

REMARKS

Claims 1-14, 16-18 and 33-37 are now pending in the present application. The recent telephone discussion with Examiner Pak is hereby noted with appreciation. Claims 12-14 and 16-17 are drawn to the elected invention. The allowance of claim 14 is also hereby noted. Claims 1-11, 18 and 33-37 are directed to non-elected invention and may be canceled by the examiner upon the allowance of the claims directed to the elected invention. Claims 12, 13, 16 and 17 have been amended to recite "isolated natural enzyme" in place of "natural enzyme".

The objection concerning compliance with the Sequence requirements has been overcome by the amendment to the specification to also identify the nucleic acid sequence as SEQ ID NO. 2 as discussed during said telephone discussion.

Claims 12, 13, 16 and 17 were rejected under 35 USC 112, first paragraph. The rejection of claims 12, 13, 16 and 17 has been overcome by the amendments to these claims to recite "isolated natural enzyme" in place of "natural enzyme" and/or is not deemed tenable. In view of this amendment, these claims no longer include variants, mutants and recombinants.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

In the event that the Examiner believes that a telephonic interview would advance the prosecution of this application, the undersigned is available at the phone number noted below.

Application No. 10/669,503
Amendment dated
After Final Office Action of December 21, 2006

Docket No.: 21581-00256-US1

Please charge any fee that is due with this response to our Deposit Account No. 22-0185,
under Order No. 21581-00256-US1 from which the undersigned is authorized to draw.

Dated: 3-16-07

Respectfully submitted,

By 

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111 (Phone)

(202) 293-6229 (Fax)

Attorney for Applicant